Table 3.
Associations between characteristics of BZD use and RT in 419 BZD users
| Characteristics of BZD use | n | Univariate analysis | Adjusted model§ | ||
|---|---|---|---|---|---|
| β | P | β | P | ||
| Dose† | 419 | 0.167 | 0.001 | 0.096 | 0.03 |
| Dose*severity of depression | 419 | −0.203 | 0.22 | 0.084 | 0.57 |
| Dose*severity of anxiety | 419 | −0.207 | 0.18 | 0.106 | 0.44 |
| Duration of BZD use | 419 | 0.114 | 0.02 | 0.036 | 0.40 |
| Type of BZD | 419 | 0.115 | 0.02 | −0.013 | 0.77 |
| Problematic use‡ | 366 | 0.190 | <0.001 | 0.118 | 0.02 |
| Preoccupation‡ | 366 | 0.110 | 0.04 | 0.023 | 0.64 |
| Lack of compliance‡ | 366 | 0.210 | <0.001 | 0.070 | 0.17 |
†Daily dose is entered as a continuous variable. ‡Subscales of the Benzodiazepine Dependence Self Report Questionnaire. §The adjusted models were adjusted for sociodemographics (gender, age, education), health indicators (daily alcohol use, presence of somatic disease), severity of psychopathology (IDS-mc, BAI), and antidepressant use (SSRI, TCA, Other Antidepressants). BZD; benzodiazepines, β; standardized β coefficient by linear regression analyses. Values in bold are significant (P < 0.05).